ALL. B

Procedura selettiva di chiamata per n. 1 posto di **Ricercatore a tempo determinato - Tipologia B** presso il Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso – Nesmos, Facoltà di Medicina e Psicologia, Settore Scientifico-disciplinare MED/26 Settore concorsuale 06/D6 di cui al bando emanato con D.R. n. 3227/2021 del 02.12.2021 con avviso pubblicato sulla G.U. – IV serie speciale n. 103 in data 28/12/2021, codice concorso 2021RTDB023.

SILVIA ROMANO
Curriculum Vitae

Part I – General Information

Full Name	Silvia Romano
Citizenship	Italian
Spoken Languages	Italian, English

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,…)
University Degree	2000	"Sapienza" University of Rome	University Degree in Medicine, grades 110/110 "cum laude", degree thesis title: "Possible risk factors in supranuclear progressive palsy", Tutor: **Prof. Cesare Fieschi**
Medical Licensure	2001	Order of Physicians, Rome	Medical License Number 51187
Specialty	2006	"Sapienza" University of Rome	Specialty Degree in Neurology, grades 70/70 "cum laude", thesis title "Episodic ataxia type 2: clinical and genetic study in Italian families", Tutor **Prof. Marco Salvetti,** Cotutor **Dr. Caterina Mariotti**
PhD	2010	"Sapienza" University of Rome	Clinical and Experimental Neurosciences, thesis "Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled trial", Tutor **Dr. Giovanni Ristori**
Master	2017	"Sapienza" University of Rome	Methodologies for therapeutic development in Neurology

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position

2nd November 2009	1st May 2010	Neurobiology and Molecular Medicine Institute – CNR Rome	Clinical and Research Fellow
1st December 2012	30th November 2013	Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome	Clinical and Research Post-doctoral Fellow
13th January 2014	12th January 2019	Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome	Researcher
1st April 2019	15th August 2020	Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome	Clinical and Research Post-doctoral Fellow

IIIB – Other Appointments

Start	End	Institution	Position
Feb 2008	June 2008	Biochemical and Genetic Unit, Carlo Besta Foundation-Neurological Institute, IRCCS, Milan	Research Consultant, "EUROSCA-European Integrated Project on Spinocerebellar Ataxias: Pathogenesis, Genetics, Animal model – CT 2003.503304 – RB13". Tutor **Dr. Caterina Mariotti**
Nov 2008	Sept 2009	Clinical and Behavioural Neurology Laboratory, IRCCS, Santa Lucia Foundation, Rome	Research Fellow, project on neurocognitive pattern of Multiple Sclerosis patients. Tutor **Dr. Ugo Nocentini**
2006	Ongoing	Italian Huntington Disease Association (AICH) - Rome	Consultant, clinical evaluation and treatment of Huntington disease patients
2013	Ongoing	Neurology Unit, S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome	Research Consultant, "REGISTRY 3.0 version - an observational study of the European Huntington-Disease Network (EHDN)". Tutor **Dr. Giovanni Ristori**
2010	2013	Neurology Unit, S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome	Research Fellow, "Efficacy of riluzole in hereditary cerebellar ataxia: a randomized double-blind placebo-controlled trial", FARM7KAJM7". Tutor **Dr. Giovanni Ristori**
Jan 2021	July 2021	Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome	Consultant neurologist, research activities
15th Aug 2020	Ongoing	ASL Rome 2 - Service dedicated to adults with disabilities - 6th District	Medical Assistant

Part IV – Teaching experience

Year	Institution	Lecture/Course
2006-2011	II Faculty of Medicine, "Sapienza" University of Rome, Physiotherapy degree course	Cerebellar disorders
2016-2019	II Faculty of Medicine and Psychology, "Sapienza" University of Rome, Medical degree course	Neurology: Huntington disease
2015-2018	II Faculty of Medicine and Psychology, "Sapienza" University of Rome, Health professions of rehabilitation sciences degree course	Evidence-Based Rehabilitation

Part V - Society memberships, Awards and Honors

Year	Title
2008	Member of the Italian Society of Neurology (SIN)
2008	Member of the European Huntington Disease Network (EHDN)
2009-2019	Member of the Scientific Committee of Pe.R.Ma.NO Onlus
2009	Member of the Scientific Committee of Italian Huntington Disease Association (AICH) –Rome
2016-2018	Member of Scientific Board of PhD in Sensorineural Plasticity, NESMOS Department University of Rome Sapienza
2018	Member of the SIN Neurogenetics and Rare Neurologic Diseases Scientific Group
2018	Member of the Physiotherapy Working Group of the EHDN
2018	Review editor - Frontiers in Paediatric Neurology
2021	Member of the Italian Association of Neuroimmunology (AINI)

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2006	Effects of tetrahydrobiopterin (6R BH4) on flow-mediated dilatation in CADASIL patients: a randomized controlled trial. EudraCT number 2007-004370-55"	II-III phase clinical trial in CADASIL. Funding Agency: Italian Medicines Agency (AIFA). (I)	20.000 €
2007	Aetiology and Immunopathogenesis of Multiple Sclerosis, and the role of exogenous virus and endogenous retroviruses.	Scientific project that aims to identify aetiology and immunopathogenesis of Multiple Sclerosis. Funding Agency: Ministry of Health (Strategic Project). (I)	130.000 €
2009	Efficacy of riluzole in hereditary cerebellar ataxia: a randomized double-blind placebo-controlled trial – FARM7KAJM7. Investigator	II-III phase clinical trial in cerebellar ataxia patients. Funding agency: Italian Medicines Agency (AIFA). (I)	150.000 €

2009	Virus and therapy in multiple sclerosis, a phase II multicenter, double-blind, randomized, placebo-controlled study of low-dose hydroxyurea in patients with primary progressive multiple sclerosis.	Phase II multicenter clinical trial. Funding agency: Ministry of Health (Strategic Project). (I)	135.000 €
2010	Non-inferiority trials for cutting drug expenses in neurology: comparing 2 interferon beta 1b regimens in Multiple Sclerosis.	Phase III clinical trial. Funding agency: Ministry of Health (Strategic Project). (I)	150.000 €
2011	Gut and Multiple Sclerosis: are MAIT cells the link?	Association-pour-la-Recherche-sur-la-Sclérose-En-Plaques (ARSEP) (I)	150.000 €
2013	An Italian study on intermediate length polyQ-tract expansions: frequency, clinical variability, and brain morphometry of subjects at risk for late-onset neurodegerative disease.	Ministry of Health GR-2013-02357821 (PI)	285.550 €
2014	Circulating non-coding RNAs in Huntington disease	Sapienza University Grant (PI)	9.000 €
2014	A "candidate interactome" approach in multiple sclerosis: from gene-environment interplay to therapeutic target hunting	Italian Multiple Sclerosis Society Foundation (FISM) (PI)	30.000 €
2016	Bacille Calmette-Guérin (BCG) vaccine in radiologically isolated syndrome (RIS)	Italian Multiple Sclerosis Society Foundation (FISM) (I)	417,850 €
2016	Riluzole in patients with spinocerebellar ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase	III phase clinical trial in patients with cerebellar ataxia type 7. Funding agency: Italian Medicines Agency AIFA-2016-02365063 (I)	275.980 €

Part VII – Organization of conferences and symposia

Date	Title
30th November 2017	PROGETTO ESCO ESPERIENZE e CONDIVISIONE nella gestione del paziente con SCLEROSI MULTIPLA Il trattamento del paziente con attività di malattia lieve-moderata: esperienze a confronto.
9th February 2018	PROGETTO ESCO ESPERIENZE e CONDIVISIONE nella gestione del paziente con SCLEROSI MULTIPLA Il trattamento del paziente con attività di malattia lieve-moderata. "Dai Real World Data alla Pratica Clinica: L'esperienza con Dimetilfumarato",

15th June 2021	The differential diagnosis of MS and monogenic demyelinating diseases - Italian Multiple Sclerosis Society (AISM)

Part VIII – Conference presentations

Date	Title
26th May 2001	I disturbi della deglutizione nella malattia di Huntington – AICH Roma Onlus
30th January 2003	BCG nella sclerosi multipla - 5th MULTIPLE SCLEROSIS LAB RETREAT
21st April 2007	Nuove opportunità terapeutiche nella gestione della Sclerosi Multipla recidivante remittente - Corso di formazione per neurologi, neuroradiologi, farmacisti e I.P.
1st October 2007	La Malattia di Alexander - Attività diagnostico-terapeutiche. Sapienza Università di Roma
19th March 2009	Aspetti cognitivi nella MH: clinica e terapia. Congresso "Tra promettenti scoperte e deludenti inadempienze: come reggere il peso della Malattia di Huntington?" – AICH Roma Onlus
23rd November 2009	Patterns of cognitive dysfunction in relapsing remitting, secondary and primary progressive multiple sclerosis: an Italian multi-centre study. XL Congress of the Italian Neurological Society.
24th October 2012	Advisory Board sull'utilizzo dei NAbs e dell'attività biologica dell'IFN beta
27th November 2015	Tavola rotonda: Realtà della diagnostica genetico-molecolare nel Lazio – Convegno Regionale SIN SNO Lazio, Seconda edizione - Roma
9th April 2016	FRDA e Riluzolo - Meeting annuale Associazione Italiana Sindromi Atassiche 2016, Roma
16th April 2016	SCA2 - Generalità, epidemiologia e storia naturale - Convegno "Atassia spino cerebellare tipo 2 (SCA2): dalla genetica alla presa in carico dei pazienti", Viterbo
10th October 2016	Contributo di una adeguata alimentazione sul sistema immunitario; Congresso "IMPATTO DELLO STILE DI VITA SUL DECORSO DELLA SCLEROSI MULTIPLA", Consiglio Regionale del Lazio, Roma
25th November 2016	Discussant "Emergenze malattie croniche come prevenire, riconoscere, gestire". Convegno Regionale SIN SNO Lazio Terza edizione
20th May 2017	Scusi dottore è vero che…? "Trattamenti farmacologici della malattia di Huntington: dalla piattaforma di Enroll-HD la ricchezza di dati che accelera la sperimentazione di nuove sostanze e tecniche". Associazione Italiana Corea di Huntington.
30th May 2017	Studio della "noise" di espressione genica di singola cellula in linee cellulari linfoblastoidi di gemelli discordanti per sclerosi multipla, pazienti sporadici e controlli. Congresso Scientifico AISM e la sua Fondazione 2017 "Insieme cambiamo la realtà della sclerosi multipla
10th April 2018	SEVEN Interactive workshop on multiple sclerosis. Policlinico Gemelli di Roma.
9th June 2018	"Le parole che non ti ho detto!" SEGRETI E BUGIE NEL RAPPORTO MEDICO-PAZIENTE: IL RICORSO ALLE MEDICINE "ALTERNATIVE" DA PARTE DI PAZIENTI CON MALATTIA DI HUNTINGTON E PERSONE A RISCHIO". Associazione Italiana Corea di Huntington Roma
12th November 2018	"Riparare il danno: Agenti rimielinizzanti, trapianto di cellule staminali stato dell'arte"- LE FORME PROGRESSIVE DI SCLEROSI MULTIPLA: UNA SFIDA DEL PASSATO, UNA COMPLESSITÀ OGGI AFFRONTABILE. Consiglio Regionale del Lazio, Sala Mechelli, Via della Pisana 1301, Roma
31st March 2019	Io e la SM: Mi metto in gioco, L'accettazione di sè. AISM, Roma

18th May 2019	Annunciata una nuova via per la cura della malattia di Huntington: la terapia genica. "Nuovi aggiornamenti sulla sperimentazione GENERATION HD! (RG6042-Roche)" Associazione Italiana Corea di Huntington,
29th November 2020	"A clinical and epidemiological prevalence study on Friedreich's Ataxia in Latium, Italy." - 51° National Congress of the Italian Society of Neurology (SIN)
27th November 2021	Terapie emergenti nella corea di Huntington: novità dalle sperimentazioni cliniche – AICH Roma Onlus
29th November 2021	Sclerosi Multipla l'altra faccia della luna. Consiglio Reginale del Lazio - Roma

Part IX – Research Activities

Keywords	Brief Description
Hereditary Cerebellar Ataxias	2006-present
	Clinical features, management and treatment of hereditary cerebellar ataxias (Spinocerebellar ataxias and Episodic Ataxia type 2).
	Principal investigator or sub-investigator in several trials with therapeutic agents for cerebellar ataxias: 1) Effects of tetrahydrobiopterin (6R BH4) on flow-mediated dilatation in CADASIL patients: a randomised controlled trial (AIFA); 2) Riluzole in cerebellar ataxia (no profit study); 3) Betamethasone in Episodic Ataxia" (no profit study); 4) Efficacy of riluzole in hereditary cerebellar ataxia: a randomized double-blind placebo-controlled trial (AIFA); 5) Riluzole in patients with spinocerebellar ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase (AIFA).
	Member of the GRASP (Ataxias and Spastic Paraplegia Group – Latium)
Huntington Disease	2006-present
	Clinical features, management and treatment of Huntington disease.
	Investigator in: 1) REGISTRY 3.0 version - an observational study of the European Huntington-Disease Network (EHDN); 2) A randomized, multicenter, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in patients with manifest Huntington's disease, ROCHE; 3) Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort.
Multiple Sclerosis	2001- present
	Aetiopathogenesis, cognitive impairment and treatment of Multiple Sclerosis.
	Investigator in National and International phase II and III trials with therapeutic agents for MS: 1) BCG in multiple sclerosis; 2) hydroxyurea in primary progressive multiple sclerosis (Ministry of Health); 3) Observational study of beta 1-a interferon in RRSM patients (SURROGATE), Merk- Serono; 4) Natalizumab in SPSM patients (ASCEND), (Biogen-Idec); MT1303E05 in RRSM patients, (MOMENTUM), Mitsubishi Tanabe.
	Responsible of the "Italian Multiple Sclerosis Register" supported by FISM Onlus from 2015 (S.Andrea Hospital)
CADASIL	2006-present
	Diagnosis, treatment and follow-up of CADASIL patients.
	Member of the International CADASIL research group - Prof. Paulsen Jane University of Iowa (2018-2020)
Alexander disease	2006- present
	Clinical features, management and treatment of adult-onset form of Alexander disease.

Parkinsonism	1999-2001
	Epidemiology and clinical features of Parkinsonism.

Part X – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	138	WOS	2001	2022
Papers [national]	2	Google Scholar	1999	2011
Books [scientific]	4	Google Scholar	2011	2018
Books [teaching]	2	Google Scholar	2017	2019

Total Impact Factor	444,392 (WOS)
Total Citations	2970 (WOS)
Average Citations per Product	21,5 (WOS)
Hirsch (H) Index	27 (WOS)
Normalized H Index*	1,29 (WOS)

*H index divided by the academic seniority.

Part XI– Selected Publications

1. Eleuteri C, Olla S, Veroni C, Umeton R, Mechelli R, Romano S, Buscarinu MC, Ferrari F, Calò G, Ristori G, Salvetti M, Agresti C. A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. Sci Rep. 2017 Apr 7;7:45780. **I.F. 4.122, Cit 20**

2. Buscarinu MC, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi M, Mechelli R, Romano S, Fornasiero A, Mattei G, Piras E, Angelini DF, Battistini L, Simmaco M, Umeton R, Salvetti M, Ristori G. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study. Mult Scler. 2017 Mar;23(3):442-446. **I.F. 5.280, Cit 65**

3. Olivito G, Cercignani M, Lupo M, Iacobacci C, Clausi S, Romano S, Masciullo M, Molinari M, Bozzali M, Leggio M. Neural substrates of motor and cognitive dysfunctions in SCA2 patients: A network based statistics analysis. Neuroimage Clin. 2017 Mar 25;14:719-725. **I.F. 3.869, Cit 20**

4. Buscarinu MC, Romano S, Mechelli R, Pizzolato Umeton R, Ferraldeschi M, Fornasiero A, Reniè R, Cerasoli B, Morena E, Romano C, Loizzo ND, Umeton R, Salvetti M, Ristori G.

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2017 Nov 8. doi: 10.1007/s13311-017-0582-3. **I.F. 5.719, Cit 27**

5. Olivito G, Lupo M, Iacobacci C, Clausi S, Romano S, Masciullo M, Molinari M, Cercignani M, Bozzali M, Leggio M. Microstructural MRI Basis of the Cognitive Functions in Patients with Spinocerebellar Ataxia Type 2. Neuroscience. 2017 Dec 16;366:44-53. **I.F. 0.929, Cit 17**

6. Romano S, Tacchella A Ferraldeschi M, Salvetti M, Zaccaria A, Crisanti A, Grassi F. Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study. F1000Res. 2017 Dec 22;6:2172 **I.F. na, Cit 13**

7. Olivito G, Lupo M, Iacobacci C, Clausi S, Romano S, Masciullo M, Molinari M, Cercignani M, Bozzali M, Leggio M. Structural cerebellar correlates of cognitive functions in spinocerebellar ataxia type 2. J Neurol. 2018 Mar;265(3):597-606. **I.F. 4.204, Cit 22**

8. Coarelli G, Romano S, Travaglini L, Ferraldeschi M, Nicita F, Spadaro M, Fornasiero A, Frontali M, Salvetti M, Bertini E, Ristori G. Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clin Neurol Neurosurg. 2018 Mar 3;168:60-63. **I.F. 1.672, Cit 7**

9. Lupo M, Olivito G, Iacobacci C, Clausi S, Romano S, Masciullo M, Molinari M, Cercignani M, Bozzali M, Leggio M. The cerebellar topography of attention sub-components in spinocerebellar ataxia type 2. Cortex. 2018 Jul 31;108:35-49. **I.F. 4.275, Cit 8**

10. Annibali V, Umeton R, Palermo A, Severa M, Etna MP, Giglio S, Romano S, Ferraldeschi M, Buscarinu MC, Vecchione A, Annese A, Policano C, Mechelli R, Pizzolato Umeton R, Fornasiero A, Angelini DF, Guerrera G, Battistini L, Coccia EM, Salvetti M, Ristori G. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. J Neuroimmunol 2018; 324(15): 165-171. **I.F. 2.832, Cit 4**

11. Ristori G, Faustman D, Matarese G, Romano S, Salvetti M. Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. Curr Opin Immunol. 2018 Dec;55:89-96. **I.F. 7.667, Cit 19**

12. Castaldo I, De Rosa M, Romano A, Zuchegna C, Squitieri F, Mechelli R, Peluso S, Borrelli C, Del Mondo A, Salvatore E, Vescovi LA, Migliore S, De Michele G, Ristori G, Romano S, Avvedimento EV, Porcellini A. DNA damage signatures in peripheral blood cells as

biomarkers in prodromal huntington disease. Ann Neurol. 2019 Feb;85(2):296-301. **I.F. 9.037, Cit 12**

13. La Starza S, Ferraldeschi M, Buscarinu MC, Romano S, Fornasiero A, Mechelli R, Umeton R, Ristori G, Salvetti M. Genome-Wide Multiple Sclerosis Association Data and Coagulation. Front Neurol. 2019 Feb 14;10:95. **I.F. 2.889, Cit 3**

14. Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Front Neurol. 2019 Jul 16;10:695. **I.F. 2.889, Cit 3**

15. Buscarinu MC, Fornasiero A, Romano S, Ferraldeschi M, Mechelli R, Reniè R, Morena E, Romano C, Pellicciari G, Landi AC, Salvetti M, Ristori G. The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Front Immunol. 2019 Aug 28;10:1916. **I.F. 5.085, Cit 16**

16. Prosperini L, Cortese A, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Capone F, Centonze D, De Fino C, De Pascalis D, Fantozzi R, Ferraro E, Filippi M, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia G, Mataluni G, Millefiorini E, Mirabella M, Monteleone F, Nociti V, Pontecorvo S, Romano S, Ruggieri S, Salvetti M, Tortorella C, Zannino S, Di Battista G. Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. J Neurol 2019. **I.F. 3.956, Cit 3**

17. Mechelli R, Umeton R, Manfrè G, Romano S, Buscarinu MC, Rinaldi V, Bellucci G, Bigi R, Ferraldeschi M, Salvetti M, Ristori G. Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. Genes (Basel). 2020 Jan 14;11(1):97. **I.F. 4.096, Cit 1**

18. Tiano F, Amati F, Cherubini F, Morini E, Vancheri C, Maletta S, Fortuni S, Serio D, Quatrana A, Luffarelli R, Benini M, Alfedi G, Panarello L, Rufini A, Toschi N, Frontali M, Romano S, Marcotulli C, Casali C, Gioiosa S, Mariotti C, Mongelli A, Fichera M, Condò I, Novelli G, Testi R, Malisan F. Frataxin deficiency in Friedreich's ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. Hum Mol Genet. 2020 Feb 1;29(3):471-482. **I.F. 6.150, Cit 3**

19. Buscarinu MC, Fornasiero A, Ferraldeschi M, Romano S, Reniè R, Morena E, Romano C, Pellicciari G, Landi AC, Fagnani C, Salvetti M, Ristori G. Disentangling the molecular mechanisms of multiple sclerosis: The contribution of twin studies. Neurosci Biobehav Rev. 2020 Apr;111:194-198. **I.F. 8.989, Cit 4**

20. Olivito G, Siciliano L, Clausi S, Lupo M, Romano S, Masciullo M, Molinari M, Cercignani M, Bozzali M, Leggio M. Functional Changes of Mentalizing Network in SCA2 Patients: Novel Insights into Understanding the Social Cerebellum. Cerebellum 2020; Apr;19(2):235-242. **I.F. 3.847, Cit 5**

21. Chesi P, Marini MG, Mancardi GL, Patti F; SMART study project group, Alivernini L, Bisecco A, Borriello G, Bucello S, Caleri F, Cavalla P, Cocco E, Cordioli C, Di Giuseppe M, Fantozzi R, Gattuso M, Granella F, Liguori M, Locatelli L, Lugaresi A, Marangoni S, Moiola L, Mutta E, Neri W, Pastò L, Perini P, Petruzzo M, Plewnia K, Repice AM, Rezzonico M, Romano S, Rovaris M, Sessa E, Tortorella C, Totaro R, Valentino P. Listening to the neurological teams for multiple sclerosis: the SMART project. Neurol Sci. 2020 Mar 20 **I.F. 3.307, Cit 3**

22. Seccia R, Gammelli D, Dominici F, Romano S, Landi AC, Salvetti M, Tacchella A, Zaccaria A, Crisanti A, Grassi F, Palagi L. Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis. PLoS One. 2020;15(3):e0230219. **I.F. 3.240, Cit 8**

23. Nicita F, Ginevrino M, Travaglini L, D'Arrigo S, Zorzi G, Borgatti R, Terrone G, Catteruccia M, Vasco G, Brankovic V, Siliquini S, Romano S, Veredice C, Pedemonte M, Armando M, Lettori D, Stregapede F, Bosco L, Sferra A, Tessarollo V, Romaniello R, Ristori G, Bertini E, Valente EM, Zanni G. Heterozygous KIF1A variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders [published online ahead of print, 2020 Jul 31]. J Med Genet. 2020. **I.F. 6.318, Cit 3**

24. Seccia R, Romano S, Salvetti M, Crisanti A, Palagi L, Grassi F. Machine Learning Use for Prognostic Purposes in Multiple Sclerosis. Life (Basel). 2021 Feb 5;11(2):122. **I.F. na, Cit 1**

25. Mechelli R, Romano S, Romano C, Morena E, Buscarinu MC, Bigi R, Bellucci G, Reniè R, Pellicciari G, Salvetti M, Ristori G. MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. Microorganisms. 2021 May 24;9(6):1132. **I.F. na, Cit 4**

26. Angeloni B, Bigi R, Bellucci G, Mechelli R, Ballerini C, Romano C, Morena E, Pellicciari G, Reniè R, Rinaldi V, Buscarinu MC, Romano S, Ristori G, Salvetti M. A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. Int J Mol Sci. 2021 Apr 2;22(7):3696. **I.F. na, Cit 1**

27. Romano S, Ferraldeschi M, Giglio S, Romano C, Morena E, Mechelli R, Annibali V, Ubaldi M, Buscarinu MC, Umeton R, Sani G, Vecchione A, Salvetti M, Ristori G. Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. Front Neurol. 2021 May 5;12:657973. **I.F. na, Cit 0**

28. Migliore S, D'Aurizio G, Maffi S, Ceccarelli C, Ristori G, Romano S, Castaldo A, Mariotti C, Curcio G, Squitieri F. Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross-sectional study. Brain Behav. 2021 Jul;11(7):e02151. **I.F. na, Cit 1**

29. Clausi S, Olivito G, Siciliano L, Lupo M, Bozzali M, Masciullo M, Molinari M, Romano S, Leggio M. The neurobiological underpinning of the social cognition impairments in patients with spinocerebellar ataxia type 2. Cortex. 2021 May;138:101-112. **I.F. na, Cit 2**

30. Buscarinu MC, Gargano F, Lionetto L, Capi M, Morena E, Fornasiero A, Reniè R, Landi AC, Pellicciari G, Romano C, Mechelli R, Romano S, Borsellino G, Battistini L, Simmaco M, Fagnani C, Salvetti M, Ristori G. Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate. Front Neurol. 2021 Aug 26;12:683398. **I.F. na, Cit. 0**

Rome, 23rd January 2022